keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker lymphoma

keyword
https://www.readbyqxmd.com/read/29674626/prognostic-significances-of-overexpression-myc-and-or-bcl2-in-r-chop-treated-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis
#1
Lu Li, Yanyan Li, Ximei Que, Xue Gao, Qian Gao, Mingxing Yu, Kaili Ma, Yanfeng Xi, Tong Wang
Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study followed the guidelines of PRISMA and Cochrane handbook. The hazard ratios (HRs) for overall survival (OS) were pooled to estimate the main effect size...
April 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29674443/recent-advances-in-the-treatment-of-peripheral-t-cell-lymphoma
#2
REVIEW
Kamel Laribi, Mustapha Alani, Catherine Truong, Alix Baugier de Materre
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting in a deeper understanding of the natural history and biology of PTCL based on molecular profiling and next-generation sequencing, there is a need for improvement in efficacy of chemotherapeutic regimens for newly diagnosed patients. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are associated with a high failure rate and frequent relapses...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29669701/crizotinib-in-patients-with-advanced-inoperable-inflammatory-myofibroblastic-tumours-with-and-without-anaplastic-lymphoma-kinase-gene-alterations-european-organisation-for-research-and-treatment-of-cancer-90101-create-a-multicentre-single-drug-prospective-non
#3
Patrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Sandra J Strauss, Silvia Stacchiotti, Piotr Rutkowski, Lars H Lindner, Michael G Leahy, Antoine Italiano, Nicolas Isambert, Maria Debiec-Rychter, Raf Sciot, Thomas Van Cann, Sandrine Marréaud, Axelle Nzokirantevye, Sandra Collette, Agnieszka Wozniak
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK)...
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29667176/pre-diagnostic-blood-immune-markers-incidence-and-progression-of-b-cell-lymphoma-and-multiple-myeloma-univariate-and-functionally-informed-multivariate-analyses
#4
Roel Vermeulen, Fatemeh Saberi Hosnijeh, Barbara Bodinier, Lützen Portengen, Benoît Liquet, Javiera Garrido-Manriquez, Henk Lokhorst, Ingvar A Bergdahl, Soterios A Kyrtopoulos, Ann-Sofie Johansson, Panagiotis Georgiadis, Beatrice Melin, Domenico Palli, Vittorio Krogh, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Raphaële Castagné, Marc Chadeau-Hyam
Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years prior to diagnosis (range, 2.01-15.97) in 268 incident cases of BCL (including multiple myeloma) and matched controls...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29666304/strategic-therapeutic-targeting-to-overcome-venetoclax-resistance-in-aggressive-b-cell-lymphomas
#5
Lan V Pham, Shengjian Huang, Hui Zhang, Jun Zhang, Taylor Bell, Shouhao Zhou, Elizabeth Pogue, Zhiyong Ding, Laura Lam, Jason R Westin, R Eric Davis, Ken H Young, L Jeffrey Medeiros, Richard J Ford, Krystle Nomie, Liang Zhang, Michael Wang
PURPOSE: B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein often dysregulated in B-cell lymphomas, promotes cell survival and provides protection from stress. A recent Phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%. These promising clinical results prompted our examination of the biological effects and mechanism of action underlying venetoclax activity in aggressive B-cell lymphoma, including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL)...
April 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29665941/-research-on-ralation-of-long-non-coding-rna-with-diffuse-large-b-cell-lymphomas-review
#6
Yan-Yuan Wu, Yi-Ran Xing, Duo-Nan Yu
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% of the non-Hodgkin's lymphoma patients. The underlying molecular mechanism of its pathogenesis is not well defined and the survival rate of DLBCL patients is very low. Moreover, the annual incidence and mortality of DLBCL is still rising. Accordingly, identification and characterization of new molecular pathways of DLBCL will lead to the development of novel diagnostic markers and molecular therapeutic targets. Long non-coding RNAs (LncRNA) are non-coding RNAs with a length greater than 200 bp in eukaryotic cells, which can regulate the expression of their target genes at the transcriptional and post transcriptional levels...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29620256/kifc1-a-novel-potential-prognostic-factor-and-therapeutic-target-in-hepatocellular-carcinoma
#7
Xiaowei Fu, Yaqiong Zhu, Bingbing Zheng, Yeqing Zou, Chao Wang, Peng Wu, Jun Wang, Haimin Chen, Pengcheng Du, Bo Liang, Lu Fang
Kinesin family member C1 (KIFC1, also known as HSET) is a minus end-directed motor protein, which is critical in centrosome clustering. The present study investigated the expression of KIFC1 in paired hepatocellular carcinoma (HCC) tissues and adjacent non-cancerous tissues from 91 patients by immunohistochemical analysis; clinical data were concomitantly collected. KIFC1 was expressed at high levels in HCC tissues, compared with that in peritumoral tissues (54.9 vs. 14.3%; P<0.01), and its expression correlated with tumor emboli, metastasis, recurrence and time of recurrence...
March 29, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29616457/presepsin-as-a-diagnostic-marker-of-bacterial-infections-in-febrile-neutropenic-pediatric-patients-with-hematological-malignancies
#8
Ahmad Baraka, Marwa Zakaria
Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study...
April 3, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29587466/chromosomal-instability-in-hodgkin-lymphoma-an-in-depth-review-and-perspectives
#9
REVIEW
Corina Cuceu, William M Hempel, Laure Sabatier, Jacques Bosq, Patrice Carde, Radhia M'kacher
The study of Hodgkin lymphoma (HL), with its unique microenvironment and long-term follow-up, has provided exceptional insights into several areas of tumor biology. Findings in HL have not only improved our understanding of human carcinogenesis, but have also pioneered its translation into the clinics. HL is a successful paradigm of modern treatment strategies. Nonetheless, approximately 15-20% of patients with advanced stage HL still die following relapse or progressive disease and a similar proportion of patients are over-treated, leading to treatment-related late sequelae, including solid tumors and organ dysfunction...
March 26, 2018: Cancers
https://www.readbyqxmd.com/read/29575092/novel-biomarker-phosphorylated-t-lak-cell-originated-protein-kinase-p-topk-can-predict-outcome-in-primary-central-nervous-system-lymphoma
#10
Masaki Koh, Yumiko Hayakawa, Takuya Akai, Tomohide Hayashi, Takahiro Tomita, Shoichi Nagai, Satoshi Kuroda
This study aimed to assess whether T-lymphokine-activated killer cell-originated protein kinase (TOPK) can be a potent novel biomarker to predict the outcome in patients with primary central nervous system lymphoma (PCNSL). This study enrolled 20 patients who were histologically diagnosed as having diffuse large B-cell type PCNSL between 2005 and 2015. Using surgical specimens, the expression of TOPK and phosphorylated TOPK (p-TOPK) was analyzed on immunohistochemistry. Clinical features such as age, sex, Karnofsky performance status (KPS), ocular involvement, deep brain structure involvement, the number of lesions, chemotherapy and radiation therapy were also collected...
March 25, 2018: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/29572581/marginal-zone-lymphoma-clinicopathologic-variations-and-approaches-to-therapy
#11
REVIEW
Sabarish Ayyappan, Basem M William
PURPOSE OF REVIEW: The purpose of the study is to summarize the current conundrums in the management of marginal zone lymphomas (MZL). RECENT FINDINGS: In 2017, the US Food and Drug Administration (FDA) approved ibrutinib, a first in class Bruton Tyrosine Kinase inhibitor, for the treatment of relapsed/refractory MZL based on pivotal open-label phase II trial demonstrating an overall response rates of 48%. Clinical trials design utilizing chemotherapy-free regimens for relapsed/refractory disease are gaining popularity...
March 23, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29564133/suitability-of-yin-yang-1-transcript-and-protein-levels-for-biomarker-studies-in-b-cell-non-hodgkin-lymphoma
#12
Jéssica Arribas Arranz, Dalia Nilufar Winter, Hans Günter Drexler, Sonja Eberth
Background: Yin Yang 1 (YY1) is a transcription factor that plays an important role during all stages of B cell differentiation. Several studies reported upregulation of YY1 in B cell derived lymphoma, indicating that it might act as an oncogene. Furthermore, aberrant YY1 expression has been associated with survival in some entities of B cell non-Hodgkin lymphoma (B-NHL), suggesting that YY1 could be a valuable biomarker in B-NHL. However, studies are controversial and methodologically disparate, partially because some studies are based on transcript levels while others rely on YY1 protein data...
2018: Biomarker Research
https://www.readbyqxmd.com/read/29559480/prognostic-model-for-high-tumor-burden-follicular-lymphoma-integrating-baseline-and-end-induction-pet-a-lysa-fil-study
#13
Anne Ségolène Cottereau, Annibale Versari, Stefano Luminari, Jehan Dupuis, Loïc Chartier, René-Olivier Casasnovas, Alina Berriolo-Riedinger, Massimo Menga, Corinne Haioun, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Gilles Salles, Judith Trotman, Michel Meignan
Both total metabolic tumor volume (TMTV), computed on baseline PET, and end of induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor burden follicular lymphoma. A model was built incorporating these two factors in 159 patients from three prospective trials. Median follow up was 64 months. High TMTV (>510cm3 ) and positive EOI PET were independent, significant risk factors for progression. Their combination stratified the population into three risk groups: patients with no risk factors (n = 102;64%) had a 5-year PFS of 67%, versus 33% (HR = 2...
March 20, 2018: Blood
https://www.readbyqxmd.com/read/29559342/microrna-signatures-in-diagnosis-and-prognosis-of-cutaneous-t-cell-lymphoma
#14
Xiaoyan Shen, Bo Wang, Kejia Li, Lili Wang, Xiaoqing Zhao, Feng Xue, Ruofei Shi, Jie Zheng
Cutaneous T cell lymphoma (CTCL) can have clinical and histological features resembling benign inflammatory dermatosis (BID) and can be difficult to diagnose. Very limited biomarkers are available for CTCL prognosis. We aimed to identify microRNA (miR) signatures to facilitate diagnostic and prognostic evaluations of CTCL. A cross-platform miR microarray identified 10 miRs that were differentially expressed between CTCL and BID patients. Subsequent RT-PCR validation was used to generate a 5-miR based diagnosing classifier, which showed high diagnostic accuracy in CTCL (AUC=0...
March 17, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29556738/aptamer-facilitated-mass-cytometry
#15
Gleb G Mironov, Alexandre Bouzekri, Jessica Watson, Olga Loboda, Olga Ornatsky, Maxim V Berezovski
Mass cytometry is a novel cell-by-cell analysis technique, which uses elemental tags instead of fluorophores. Sample cells undergo rapid ionization in inductively coupled plasma and the ionized elemental tags are then analyzed by means of time-of-flight mass spectrometry. Benefits of the mass cytometry approach are in no need for compensation, the high number of detection channels (up to 100) and low background noise. In this work, we applied a biotinylated aptamer against human PTK7 receptor for characterization of positive (human acute lymphoblastic leukemia) and negative (human Burkitt's lymphoma) cells by a mass cytometry instrument...
March 20, 2018: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/29556265/advanced-oxidation-protein-products-inhibit-the-autophagy-of-renal-tubular-epithelial-cells
#16
Jun Zhang, Xiaohong Xiang, Shuangshuang Shu, Cuiling Zhang, Yuling Liang, Tingting Jiang, Wenying Zhang, Tingting Guo, Xiujie Liang, Xun Tang
It is well known that autophagy serves a crucial role in renal tubular epithelial cell (RTEC) injury in the pathogenesis of chronic kidney disease (CKD). The accumulation of advanced oxidation protein products (AOPPs) also participates in the progression of CKD. However, the effects of AOPPs on autophagy remain unknown. To clarify the underlying mechanism of RTEC injury in CKD, the effect of AOPPs on HK-2 cells, an RTEC cell line, was investigated. The results of the present study revealed that AOPP exposure downregulated the expression of B-cell lymphoma-2-interacting myosin-like coiled-coil protein 1, reduced the conversion of microtubule-associated proteins 1 light chain 3B (LC3)-I to LC3-II and the formation of autophagosomes, and lead to an accumulation of p62...
April 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29551295/systemic-activation-of-nlrp3-inflammasome-in-patients-with-severe-primary-sj%C3%A3-gren-s-syndrome-fueled-by-inflammagenic-dna-accumulations
#17
Aigli G Vakrakou, Sorina Boiu, Panayiotis D Ziakas, Evangelia Xingi, Haralabia Boleti, Menelaos N Manoussakis
Sjögren's syndrome (SS) patients manifest high cell-free DNA (cf-DNA) levels in serum, associated with impaired DNaseI activity. Undegraded DNA may accumulate in tissues and act as an inflammasome-activating signal. Herein, we investigated the occurrence of aberrant DNA build-up in various biologic compartments of SS patients and its correlation with the activity of NLRP3 and AIM2 inflammasomes. For this purpose, we evaluated sera, PBMC, circulating monocytes and salivary glands (SG) from different SS patient subgroups and controls...
March 15, 2018: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29547001/molecular-pathology-of-lung-cancer-cytology-specimens-a-concise-review
#18
Deepali Jain, Sinchita Roy-Chowdhuri
CONTEXT: - There has been a paradigm shift in the understanding of molecular pathogenesis of lung cancer. A number of oncogenic drivers have been identified in non-small cell lung carcinoma, such as the epidermal growth factor receptor ( EGFR) mutation and anaplastic lymphoma kinase ( ALK) gene rearrangement. Because of the clinical presentation at an advanced stage of disease in non-small cell lung carcinoma patients, the use of minimally invasive techniques is preferred to obtain a tumor sample for diagnosis...
March 16, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29541388/single-cell-rna-sequencing-reveals-gene-expression-signatures-of-breast-cancer-associated-endothelial-cells
#19
Zhengda Sun, Chih-Yang Wang, Devon A Lawson, Serena Kwek, Hugo Gonzalez Velozo, Mark Owyong, Ming-Derg Lai, Lawrence Fong, Mark Wilson, Hua Su, Zena Werb, Daniel L Cooke
Tumor endothelial cells (TEC) play an indispensible role in tumor growth and metastasis although much of the detailed mechanism still remains elusive. In this study we characterized and compared the global gene expression profiles of TECs and control ECs isolated from human breast cancerous tissues and reduction mammoplasty tissues respectively by single cell RNA sequencing (scRNA-seq). Based on the qualified scRNA-seq libraries that we made, we found that 1302 genes were differentially expressed between these two EC phenotypes...
February 16, 2018: Oncotarget
https://www.readbyqxmd.com/read/29531316/rapid-real-time-pathology-review-for-ecog-acrin-1412-a-novel-and-successful-paradigm-for-future-lymphoma-clinical-trials-in-the-precision-medicine-era
#20
Rebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, David W Scott, Richard F Little, Fangxin Hong, Randy D Gascoyne, Brad S Kahl, William R Macon
ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression profiling (GEP) for cell-of-origin testing. Because of high ineligibility rate on retrospective expert central pathology review (ECPR), real-time (RT) ECPR was instituted to confirm diagnosis and ensure adequate tissue for GEP prior to study enrollment. Goal was notification of eligibility within 2 working days (WD)...
February 28, 2018: Blood Cancer Journal
keyword
keyword
7294
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"